Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

load * local 115

Keyword

Abstract--

Keyword

Abstract -+

on/HIV-1 cellular RNA
ntification of HIV-1 viral
DS: Complexity of viral
minant of the HIV-1 viral
s and its relation to viral
rognostic value of virus
zed HIV+ patients/Viral
Predictive value of viral
ve patients through viral
nfants from Africa/Viral
I pneumonitis/HIV viral
>400 cells/ttl and viral
tudy (POPS)/HIV viral
ABC) reduces CSF viral
educe CSF HIV-1 viral
-infected children/Viral
year durability of HIV-1
se inhibitors/HIV RNA
nt choice strategy/Viral
importance of HIV viral
stance mutations/Viral
ression of plasma viral
HIV-1 RNA plasma viral
'and E, Bangkok/Viral
ed infectious HIV-1 viral
/Comparison of viral
longitudinal HIV-1 viral
CD4 cell count and viral
oire/HIV-1 plasma viral
oire/HIV-1 plasma viral
racterization/High viral
n/Pattern of HIV-1 RNA
s/Virus detection, virus
ionship between HIV-1
virus/Site specific virus
vel correlates with virus
ction correlates to viral
s isolation, plasma viral
duction in plasma virus
hepatitis C viral (HCV)
c value of CSF JC viral
e inhibitor) on HCV viral
nship between HIV viral
to know the role of viral
ow baseline HIV-1 viral
ars analysis of the viral? Baseline plasma viral
troviral therapy on viral
22)/The impact of viral
dividuals/Plasma viral
es related to a high viral
northern Thailand/Viral
d Thai men/HIV-1 viral
/Changes in HIV-1 viral
users (IDU)/lnitial viral
navir/stavudine on viral
and seminal HIV-1 viral
s/Determination of viral
or CD4+ count and viral
ith HIV/AIDS/HIV viral
gerated/Spreading the
ibody and plasma viral
ymphocytes and viral
ne function and on viral
yte antibodies and viral
on correlates with viral
ase inhibitors/HCV viral
with HIV-1 plasma viral
r one year/Plasma viral
ation between the viral
Distribution of brain HIV
cell count and HIV viral
tis C virus and HIV-viral
tro correlates with viral
Atlanta, Georgia/Viral

ral resistance and viral
or AZT plus 3TC - Viral
rive and a falling viral
re associated with viral
d quantification of virus

arise in late stage of HIV-disease but 11158 Changes in plasma viral
in plasma: Influence of the HIV-1 subt 11175 n-lot variation/HIV viral
and tissue tropism in African green m 11217 sed study of HIV-2 RNA
/Haptoglobin polymorphism as deter 12115 uantitation of HIV-2 viral,and CD4+ T-cell count/The role of HI 12126 antitation of HIV-1 virus
levels in patients receiving HAART in 12129 ation tubes for HIV viral
characteristics of hospitalized HIV+ p 12132 /Response of HIV viral
and other markers for progression to 12133 U)/Assessment of viral
/Follow-up of HIV positive patients thr 12136 with HIV infection/Viral
studies in untreated infants from Afric 12154 se/Importance of CMV
in children with lymphocytic interstitial 12164 f HAART on HIV viral
>5000 copies/ml/Combination abac 286*/12204 ma and genital tract viral
response in subjects switched from zi 12228 A possible effect of viral
in HIV-infected children (CNA 3006)/ 12252 predictive value of HIV
in pediatric patients with advanced HI 12253 od to assess rectal viral
and CD4-cell count under a triple-ther 12256 evels and plasma viral
suppression in patients treated with in 12279 the assessment of viral
in blood and seminal plasma of patien 12284 ty of undetectable viral
levels during treatment with Viracept 12300 pean clinical trials/Viral
/Response to indinavir in HIV-infected 12306 esting in Ontario/Viral
reduction after changing from nelfinav 12342 d generation HIV-1 viral
below 20 copies/mL is necessary for 1 12364 ection/Changes in viral
and CD4 counts before and after anti- 13271 d the frequency of viral
and CD4 cell count in injecting drug u 191*/13302 HIV-1 cellular infectious
beneficial in predicting HIV-1 disease 13308 Analyzes of HIV-1 viral
levels between cohorts infected with 13314 d patients/Plasma viral
after seroconversion associated with 13322 bly with and add to viral
in HTLV-II and HIV co-infection in inje 13326 cell activation and viral
in tuberculosis patients with single HI 13328 une markers, and viral
and CD4 counts in surviving and non- 13329 gram for plasmatic viral
in in children long-term non progresso 13356 ynamics in plasma viral
from birth to school-age in perinatally 13361 eement regarding viral,and disease progression in perinatall 13369 tween basal HIV-1 viral
and progression to AIDS/Gender diff 13384 ) and its effects on viral
in the reproductive tract tissues of wo 13385 icali, Mexico/The viral
in pediatric HIV infection/Plasma L-s 21115 actors on plasma viral
and predicts progression of HIV disea 21132 sions, CD4 count, viral,and clinical spectrum (the HIV-2 Iberi 21154 y of negativation of viral
leads to decrease in lymphocyte apop 21163 conomic impact of viral
and serum alamine aminotransferase 22252 sm or catabolism/Viral
in patients with progressive multifocal 22266 wing an initial HIV viral
in patients co-infected with HCV-HIV/ 22269 ying HIV-1 plasma viral,CD4 level and cervicovaginal human 22313 ated access to free viral
and ARV therapies in the progression 22321 gressors with high virus
(median 4089 copies/ml)/Double (3T 22344 bility of plasma HIV viral
of participants of the Swiss HIV cohort 22346 treatment/Plasma viral
as a predictor of virologic response to 22359 nce and decrease viral
and CD4 count in HIV infected childre 22364 nterference/HIV-1 viral
(VL) nadir on the change of antiretrovi 22368 ents/Predictors of viral
reduction in an open-label randomize 22393 gy in HIV infection/Viral
under AZT treatment/Mother-to-child 23308 e progression and viral
and male to female sexual transmissi 23388 -November 1997/Viral
in blood and semen of subtype E infec 23390 e: Results on RNA viral
after discontinuation of oral AZT given 23391 retroviral therapy/Viral
(VL) soon after seroconversion (SC) h 23396 orrelation between viral
in seminal fluid and plasma compartm 23397 PI)/Comparison of viral

related to short-course oral zidovudin 33164
measurement by Amplicor HIV-1 Mon 41134
in pregnant women attending health c 165*/41135
in plasma/A competitive RT-PCR met 41136
by a TaqMan'"-based product enhanc 41137
testing/Evaluation of Vacutainer~ Br 41138
to antiretroviral mono and combinatio 41141
and CD4/CD8 ratio in blood and lymp 289*/41142
and clinical manifestations in patients 41148
as a risk factor for CMV disease/Impo 41149
and CD4 T cells in the mucosa-associ 41185
and STDs in early HIV infection/Plas 164*/42141
differences/Gender differences in ant 42145
and host genetic factor on disease pr 42146
and lymphoid architecture/Rectal sno 42147
/Cervicovaginal HIV-1 RNA levels an 42148
reduction in HIV clinical trials/Biases i 42149
(VL) in response to antiretroviral thera 42154
assays and HIV-1 subtypes in Europe 42155
testing in Ontario/Viral 42157
assays with improved lower detection 42158
during acute respiratory infections in 42161
testing on outcomes, costs and patter 42173
in peripheral blood: Evaluation and rel 42176
(bDNA) in plasma samples in pediatri 42178,CD4 count and p24 antigenemia in H 42180
and CD4 T cells as prognostic indicat 42181
in HIV-infected patients with >400 CD 42190
in HIV+ adults with CD4+ counts 200- 42328
of HIV-1 by NASBA technology in 32 I 43463
and CD4+ lymphocyte count as a res 43473
test interpretation?/A novel method t 43529
and CD4+ T cell subset in AIDS patie 60122
(VL) and CD4 count/Changing highly 60178
is not proportional inversely to the CD 60222
in patients with HIV-1 disease/Influen 60264
and other covariates in women enroll 60299
as a prognosis marker of failure in tripl 60448
driven triple drug combination antiretr 60507
response to HAART is an unpredictab 60517
test/Evaluating the appropriateness 60670
/Usefulness of the new NASBA ultras 60679
assays: VLAP (the Viral Load Access 60699
/Virological and immunological chara 60702
in Vacutainer~ plasma preparation tu 60731
in HIV-1 and HIV-2 co-infected TB pat 60742
in HIV-infected patients/Infusion of cr 60771
in Ghana (West Africa): No HIV-2 inte 60773
response in triple therapy with protea 60805: Risk independent factor for anergy in 60816
levels in a cohort of Caucasians and A 60870
determination of 700 patients infected 60941
and CD4 T cells count/Quadritherapy 60966
in HIV-1+/AIDS patients: Distribution 60979
and CD4 count in patients with and wit 60991
mean in the same center before and a 60992

in antiretroviral-naive Brazilian subjec 23399 ne on reduction of viral loads and HIV V3 sequence in HIV+ subje 21209
in breakfast and plasma in HIV infecte 23400 detectable plasma viral in 250 HIV(+) women in care/The eff 22365
in women/HIV-related symptoms by i 23456 detectable plasma viral /Perceptions, attitudes, and sexual ri 23389
in cervical, vaginal and menstrual flui 23477 nza vaccination on viral in HIV patients/Effect of influenza va 32155: Reports of the death of AIDS activis 24142 d plasma HIV-RNA viral in patients with HIV infection/Lymph 41144
in HIV infected patients receiving HA 31102 ate with increasing viral in HIV-1 infected people with differin 42186
in HIV-infected children over five year 31138 al and maintain low viral /Homeopathic growth factors suppor 60495
in lymph tissue/Effect of prolonged H 31160 a (KS) have higher viral than patients with visceral KS/Patie 60499
in AIDS patients/Anti-lymphocyte anti 31162 traepithelial neoplasia/ HIV-1 expression in the female genit 22310
and CD4+ T cell number at baseline a 116*/31170 ervice center of Manila/ government response: Homeward H 22486
in HCV-HIV-co-infected patients treat 32113 vention services at the local level/Early intervention demonstratio 13444
and are improved by highly active anti 32139 f effectiveness to meet needs/The role of teachers and unio 13507
predicts cognitive function after one y 32190 ough delay visiting their health centre in Lusaka, Zambia?/W 22133
in cerebrospinal fluid (CSF), plasma a 32201 and young adults at the level/Communities at risk- Estimatin 23546
in AIDS/Distribution of brain HIV 32203 vention/Evaluation of tolerance of a vaginal film (VF) of non 33138
on CMV retinitis treated with an impla 32243 rkshops for teens/How organizations tailor previously evalua 33439
/Erythema of the proximal nailfold in H 32268 ementing agencies and communities/Effective collaboration 34370
response to abacavir (1592, ABC) in v 231*/32289 ersons is a regional and phenomenon/Treatment information 42237
and CD4+ outcome following genotyp 32291 liminary evaluation of a phytomedicine (NIPRD 94/006/1-2) f 42389
response to abacavir (ABC, 1592) in 32293 multidrug therapies at a tertiary HIV referral centre - Impact o 42450
suppression after 12 months/d4T plu 32321 tate/Supporting AIDS hot-lines system in Sao Paulo: Strate 43215
are associated with adherence to anti 32343 V-related care: Shaping care management/Patients who trav 43517
suppression in HIV+ homeless and m 32390 nity for PLWHIV/AIDS a government initiative/Creating an e 44300
/Heat-denatured p24 antigen testing c 32442 tion forum for state and health department HIV prevention pr 44307